Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2001

View Archived Issues

Flamel Technologies completes controlled-release antibiotic study

Amgen submits supplemental application with EMEA for anemia product

Genzyme General highlights Q3 developments

Catalytic antioxidant AEOL-10150 protects hamsters against radiation-induced mucositis

Combination of CCI-779 and 5-FU/LV associated with significant toxicity in phase I study

European Generx trial approved and set to commence

Impact of addition of BMS-275291 to paclitaxel/carboplatin examined in phase II/III trial in NSCLC

Merck KGaA and Forest to comarket treatment for alcohol addiction in the U.S.

Antimicrotubule agent T-900607 well tolerated in ongoing phase I trial in advanced cancer patients

Novel platinum analogue shows evidence of activity, adequate safety in phase II cancer trials

Tissue engineering product to begin clinical trials in the U.S.

SU-5416 may be useful in certain patients with c-kit-positive AML, according to phase II data

Gilead licenses its SELEX technology to Archemix

NXY-059 may have advantages over current neuroprotectants for the treatment of stroke

Merger of Barr and Duramed finalized this week

Oxigene regains rights to anticancer combretastatins, ends development of declopramide

Novartis receives approvable letter for Diovan as treatment for heart failure

ACG news: pilot study of APC-2059 demonstrates safety and activity in ulcerative colitis

Second activated macrophage therapy trial initiated in Belgium

Novel protein identified at CuraGen shows promise in IBD

Pyrimidines inhibit CDKs and FAK according to recent AstraZeneca patent

New series synthesized at Bayer shows inhibitory activity against cGMP-PDE

Takeda discloses agents for inflammation, arthritis and bone disorders

Scios patents discoveries in the field of bradykinin antagonists

New chroman derivatives designed at Akzo Nobel with affinity for estrogen receptors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...